Oligonucleotide chemistry has been developed greatly over the past three decades, with
many advances in increasing nuclease resistance, enhancing duplex stability and assisting …

Synthetic antisense oligonucleotides (ASOs) and duplex RNAs (dsRNAs) are an
increasingly successful strategy for drug development. After a slow start, the pace of success …

Chemical modifications are necessary to ensure the metabolic stability and efficacy of
oligonucleotide-based therapeutics. Here, we describe analyses of the α-(l)-threofuranosyl …

Since its inception more than a decade ago, the field of short interfering RNA (siRNA)
therapeutics has demonstrated potential in the treatment of a wide variety of diseases. The …

Glycol nucleic acid (GNA) is an acyclic nucleic acid analog connected via phosphodiester
bonds. Crystal structures of RNA–GNA chimeric duplexes indicated that nucleotides of the …

Small interfering RNA (siRNA)‐mediated silencing requires siRNA loading into the RNA‐
induced silencing complex (RISC). Presence of 5′‐phosphate (5′‐P) is reported to be …

Oligonucleotide gene therapy (OGT) agents (eg antisense, deoxyribozymes, siRNA and
CRISPR/Cas) are promising therapeutic tools. Despite extensive efforts, only few OGT drugs …

Abstract 5΄-Vinylphosphonate modification of siRNAs protects them from phosphatases, and
improves silencing activity. Here, we show that 5΄-vinylphosphonate confers novel …

Small interfering RNAs (siRNAs) are now established as the preferred tool to inhibit gene
function in mammalian cells yet trigger unintended gene silencing due to their inherent …

Three types of highly promising small RNA therapeutics, namely, small interfering RNAs
(siRNAs), microRNAs (miRNAs) and the RNA subtype of antisense oligonucleotides (ASOs) …